Embedded Files
News
News
MyoGene Bio is Granted Orphan Drug and Rare Pediatric Disease Designations
November 19, 2024
MyoGene Bio announced today that MyoDys45-55 was recently granted Orphan Drug Designation and Rare Pediatric Disease Designation by FDA. <Read More>
MyoGene Bio is Competing in the Entrepreneurship World Cup
October 17, 2024
MyoGene Bio is excited to be one of the 100 up-and-coming startups from around the world competing in the Entrepreneurship World Cup next month in Riyadh, Saudi Arabia! <Read More>
MyoGene Bio is Advancing to the Finals of the Entrepreneurship World Cup
July 18, 2024
Dr. Courtney Young, co-founder and CEO, pitched for MyoGene Bio at the GEC+ Puerto Rico conference and was selected as one of 4 finalists to advance to the finals of the Entrepreneurship World Cup in Riyadh, Saudia Arabia. <Read More>
MyoGene Bio is a Semi-Finalist for Stella Women’s Fast Pitch
June 27, 2024
Dr. Courtney Young, Co-founder and CEO of MyoGene Bio, was selected as a semi-finalist for the Southwest region of the Stella Foundation Women’s Fast Pitch virtual competition!
MyoGene Bio Graduates from the Creative Destruction Lab Advanced Therapies Stream
May 29, 2024
MyoGene Bio has graduated from the Creative Destruction Lab (CDL)’s Advanced Therapies accelerator. We are grateful to CDL and all the mentors for their support and making it a great program!
MyoGene Bio Presents at ASGCT 2024
May 9, 2024
MyoGene Bio presented a poster at the 2024 American Society of Gene and Cell Therapy (ASGCT)’s annual conference.
MyoGene Bio Highlighted in Colorado Hometown Weekly
March 23, 2021
Courtney Young and MyoGene Bio were highlighted in an article in Colorado Hometown Weekly. <Read More>
MyoGene Bio will participate in the First Look SoCal Innovation Showcase
June 16, 2021
MyoGene Bio was highlighted as a startup participating in the First Look SoCal Innovation Showcase. <Read More>
MyoGene Bio is participating in the UC’s Startup Innovation Challenge
December 17, 2020
MyoGene Bio was selected as one of 10 startups to participate in the UC’s Startup Innovation Challenge next year. <Read More>
MyoGene Bio participates in QB3 2020 Pitch Summit and receives in-kind service from Sartorius
November 18, 2020
MyoGene Bio was selected as a cohort member of QB3’s annual Pitch Summit and received in-kind services from Sartorius. <Read More>
Funding
Funding
MyoGene Bio is Awarded an NIH Grant to Further Preclinical Development
September 1, 2024
MyoGene Bio is pleased to report additional grant funding from the National Center for Advancing Translational Sciences at the National Institutes of Health to conduct additional preclinical studies. We are greatly appreciative of their support!
MyoGene Bio is Awarded a Department of Defense Grant to Further Preclinical Development
August 1, 2024
MyoGene Bio is pleased to report additional grant funding from the Department of Defense Congressionally Directed Medical Research Program for Duchenne Muscular Dystrophy to conduct additional preclinical studies. We are greatly appreciative of their support!
MyoGene Bio receives Funding from CureDuchenne Ventures
May 11, 2023
CureDuchenne Ventures invested in MyoGene Bio and contributed co-funding for a California Institute for Regenerative Medicine grant awarded to the company. <Read More>
December 15, 2021
MyoGene Bio has received a $3.4M grant from the California Institute for Regenerative Medicine to advance preclinical development of our gene editing therapy for Duchenne. We are greatly appreciative of their support! <Read More>
MyoGene Bio is awarded a Phase I SBIR grant from NIH
September 5, 2020
MyoGene Bio was awarded a Phase I SBIR grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases at the National Institutes of Health to advance preclinical studies. We are appreciative of their support!
MyoGene Bio is awarded a Muscular Dystrophy Association research grant
September 5, 2019
MyoGene Bio was awarded a research grant from the Muscular Dystrophy Association. We appreciate their support! <Read More>
MyoGene Bio is awarded an NIH SBIR Fast-Track grant
August 1, 2019
MyoGene Bio was awarded an SBIR Fast-Track grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases at the National Institutes of Health for advancing preclinical development. We appreciate their support!
Awards
Awards
MyoGene Bio is Awarded 4th Place in the Entrepreneurship World Cup
November 11, 2024
MyoGene Bio wins 4th Place in the Early Stage competition at the Entrepreneurship World Cup at Biban24 in Riyadh, Saudi Arabia. <Read More>
November 1, 2023
Dr. Courtney Young, Co-founder and CEO of MyoGene Bio, was one of 10 Life Science Catalyst Award winners from Biocom California. <Read More>
September 12, 2023
Dr. Courtney Young, Co-founder and CEO of MyoGene Bio, was listed as one of MIT Technology Review’s 35 Innovators under 35 in Biotechnology. <Read More>
MyoGene Bio is listed as a UCLA Alumni Association’s 2023 Bruin Business 100
May 18, 2023
MyoGene Bio was listed as one of the hundred UCLA Alumni Association's Bruin Businesses this year. <Read More>
MyoGene Bio wins Second-place in the Life Science category of the Startup 302 Finals
April 28, 2023
MyoGene Bio was awarded a $12,000 prize for second-place in the life science category of the Startup 302 Finals. We appreciate their support! <Read More>
October 28, 2021
MyoGene Bio was selected for the Cydan Rare Disease Award of $20,000 from the MassChallenge 2021 US Early Stage accelerator program. We thank the program, sponsor, and mentors for their support! <Read More>
Page updated
Report abuse